A Study of the PK, Safety and Antiviral Activity of A-831 in HCV Carriers

Phase 2TerminatedNCT00522808

Arrow Therapeutics36 enrolled

Overview

The purposes of this study are: * to determine the safety and tolerability of multiple doses of A-831 at various doses * to determine how multiple doses of A-831 are distributed through the bloodstream * to determine if A-831 reduces the amount of Hepatitis C virus in the blood

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Chronic Hepatitis C

Interventions

A-831DRUG

Eligibility

Sex: MALEMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Volunteers will be males of any race aged 18-60 years with a BMI between 18 and 32 kg/m2 at the time of the screening medical * Volunteers who have given their written informed consent to participate in the study * Volunteers who are willing and able to comply with the protocol and study procedures * Volunteers who have a diagnosis of chronic hepatitis C infection and are in good health (other than history of Hepatitis C infection) Exclusion Criteria: * Voulnteers with concurrent medical conditions or taking concurrent medications

Locations (3)

ACS

Auckland, New Zealand

Birmingham WTCRF

Birmingham, United Kingdom

DDS

Dundee, United Kingdom

Outcomes

Primary Outcomes

Safety

Tolerability

Antiviral activity

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.